VTGN VistaGen Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: VTGN
Price (delayed)
$2.84
Market cap
$87.13M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.79
Enterprise value
$40.5M
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression, and
Highlights
The gross profit has contracted by 33% YoY but it has grown by 33% from the previous quarter
VistaGen Therapeutics's revenue has decreased by 33% YoY but it has increased by 33% QoQ
The net income has dropped by 68% year-on-year and by 8% since the previous quarter
VTGN's quick ratio has dropped by 67% year-on-year and by 11% since the previous quarter
Key stats
What are the main financial stats of VTGN
Market
Valuations
Earnings
Shares outstanding
30.68M
Market cap
$87.13M
Enterprise value
$40.5M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.46
Price to sales (P/S)
140.38
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
62.7
Revenue
$646,000
Gross profit
$646,000
Operating income
-$59.65M
Net income
-$55.78M
EBIT
-$55.77M
EBITDA
-$55.12M
Free cash flow
-$50.29M
Per share
Balance sheet
Liquidity
EPS
-$1.79
EPS diluted
-$1.79
Free cash flow per share
-$1.57
Book value per share
$1.95
Revenue per share
$0.02
TBVPS
$2.16
Total assets
$68.92M
Total liabilities
$12.16M
Debt
$2.36M
Equity
$56.77M
Working capital
$55.56M
Debt to equity
0.04
Current ratio
5.98
Quick ratio
5.66
Net debt/EBITDA
0.85
Margins
Efficiency
Dividend
EBITDA margin
-8,532.5%
Gross margin
100%
Net margin
-8,634.7%
Operating margin
-9,233.1%
Return on assets
-64.1%
Return on equity
-74.1%
Return on invested capital
-565.5%
Return on capital employed
-96.5%
Return on sales
-8,633.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VTGN stock price
How has the VistaGen Therapeutics stock price performed over time
Intraday
-4.38%
1 week
-2.41%
1 month
19.33%
1 year
-16.72%
YTD
-3.73%
QTD
42%
Financial performance
How have VistaGen Therapeutics's revenue and profit performed over time
Revenue
$646,000
Gross profit
$646,000
Operating income
-$59.65M
Net income
-$55.78M
Gross margin
100%
Net margin
-8,634.7%
The company's net margin has shrunk by 152% YoY but it rose by 18% QoQ
The operating margin has dropped by 135% year-on-year but it is up by 20% since the previous quarter
The net income has dropped by 68% year-on-year and by 8% since the previous quarter
The company's operating income has shrunk by 56% YoY and by 7% QoQ
Price vs fundamentals
How does VTGN's price correlate with its fundamentals
Growth
What is VistaGen Therapeutics's growth rate over time
Valuation
What is VistaGen Therapeutics stock price valuation
P/E
N/A
P/B
1.46
P/S
140.38
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
62.7
VistaGen Therapeutics's EPS has decreased by 21% YoY and by 7% from the previous quarter
The price to book (P/B) is 53% higher than the last 4 quarters average of 1.0 but 47% lower than the 5-year quarterly average of 2.9
The equity has decreased by 46% YoY and by 19% QoQ
VistaGen Therapeutics's revenue has decreased by 33% YoY but it has increased by 33% QoQ
The price to sales (P/S) is 19% higher than the last 4 quarters average of 123.2 but 19% lower than the 5-year quarterly average of 180.5
Efficiency
How efficient is VistaGen Therapeutics business performance
VistaGen Therapeutics's ROS has plunged by 152% YoY but it has increased by 18% from the previous quarter
The ROE has plunged by 111% YoY and by 26% from the previous quarter
The company's return on assets has shrunk by 98% YoY and by 22% QoQ
The company's return on invested capital rose by 38% YoY and by 4.6% QoQ
Dividends
What is VTGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VTGN.
Financial health
How did VistaGen Therapeutics financials performed over time
VTGN's quick ratio has dropped by 67% year-on-year and by 11% since the previous quarter
The current ratio has plunged by 66% YoY and by 8% from the previous quarter
The company's debt is 96% lower than its equity
VTGN's debt to equity has surged by 100% since the previous quarter and by 100% year-on-year
The company's debt has surged by 56% QoQ and by 18% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.